Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a significant increase in short interest in August. As of August 15th, there was short interest totalling 346,800 shares, an increase of 28.2% from the July 31st total of 270,600 shares. Based on an average daily volume of 384,700 shares, the short-interest ratio is presently 0.9 days. Currently, 0.5% of the company's stock are short sold.
Atyr PHARMA Stock Performance
Shares of NASDAQ ATYR traded down $0.02 during midday trading on Friday, reaching $1.87. 98,715 shares of the company were exchanged, compared to its average volume of 466,327. Atyr PHARMA has a one year low of $1.08 and a one year high of $2.50. The stock has a market cap of $129.05 million, a PE ratio of -2.08 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, equities analysts expect that Atyr PHARMA will post -0.89 EPS for the current fiscal year.
Insider Activity
In other news, Director Paul Schimmel bought 52,300 shares of the company's stock in a transaction that occurred on Wednesday, July 24th. The shares were acquired at an average price of $1.93 per share, with a total value of $100,939.00. Following the transaction, the director now owns 413,023 shares in the company, valued at $797,134.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.70% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have issued reports on the stock. Royal Bank of Canada restated an "outperform" rating and set a $16.00 price objective on shares of Atyr PHARMA in a research report on Wednesday, August 14th. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Thursday, August 15th.
Read Our Latest Research Report on ATYR
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
See Also
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
